How Can Mycins Be Distinguished?

Erythromycin, chloramphenicol, and clindamycin are all antibiotics commonly referred to as “mycins.” However, despite sharing a similar suffix, they differ significantly in their pharmacological effects and clinical applications.

There are many medications ending in “-mycin,” such as erythromycin, chloramphenicol, clindamycin, and gentamicin, which are widely used in clinical practice. So how can these “mycins” be differentiated? What are the differences in their medical uses?

Macrolide Antibiotics

Representative drugs: erythromycin, azithromycin, clarithromycin, roxithromycin, telithromycin, etc.

Antibacterial spectrum: Primarily effective against most Gram-positive bacteria, anaerobic cocci, and certain Gram-negative bacteria.

Clinical applications: Used to treat respiratory tract infections, urinary tract infections, skin and soft tissue infections, and other diseases caused by Gram-positive bacteria, some Gram-negative bacteria, Mycoplasma, Helicobacter pylori, and other susceptible organisms. Erythromycin is also effective in treating infections caused by penicillin-resistant bacteria and is suitable for patients with penicillin allergies.

Lincosamide Antibiotics

Representative drugs: lincomycin, clindamycin, etc.

Antibacterial spectrum: Mainly active against Gram-positive bacteria (excluding enterococci), some aerobic Gram-negative cocci, and a wide range of anaerobic bacteria.

Clinical applications: Used in the treatment of acute and chronic osteomyelitis, joint infections, and mixed aerobic and anaerobic infections such as peritonitis, pelvic inflammatory disease, otitis media, and sinusitis, particularly those caused by Staphylococcus aureus.

Aminoglycoside Antibiotics

Representative drugs: streptomycin, neomycin, gentamicin, kanamycin, spectinomycin, etc.

Antibacterial spectrum:

Aminoglycosides have a broad antibacterial spectrum and exhibit strong activity against a wide range of aerobic Gram-negative bacilli, including Pseudomonas aeruginosa. They are also effective against penicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant Staphylococcus epidermidis, and other Gram-positive cocci. Certain agents demonstrate significant efficacy against Mycobacterium tuberculosis, although they are generally less effective against Gram-positive bacilli and Gram-negative cocci.

Clinical applications:

These antibiotics are primarily used to treat systemic infections caused by susceptible aerobic Gram-negative bacilli. For severe infections caused by Gram-positive cocci, they are typically administered in combination with penicillin, other β-lactam antibiotics, or rifampin. In addition, streptomycin is used in the treatment of tuberculosis.

Scope of Application

Aminoglycosides are mainly indicated for systemic infections caused by sensitive aerobic Gram-negative bacteria. They are particularly effective against common pathogens such as Pseudomonas aeruginosa, Klebsiella species, and Escherichia coli. Due to their prolonged post-antibiotic effect (PAE), they are frequently used in the treatment of serious infections, including meningitis, respiratory tract infections, urinary tract infections, skin and soft tissue infections, gastrointestinal infections, burn-related infections, and bone and joint infections.

However, for severe infections caused by Gram-negative bacilli—such as septicemia, pneumonia, or meningitis—aminoglycoside monotherapy may be insufficient. In such cases, combination therapy with other agents that have strong activity against Gram-negative bacilli, such as broad-spectrum semi-synthetic penicillins, third-generation cephalosporins, or fluoroquinolones, is recommended.